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Abstract
Background: There is an increasing burden of non-communicable disease globally. Tenofovir disoproxil fumarate
(TDF) is the most commonly prescribed antiretroviral drug globally. Studies show that patients receiving TDF are
more prone to renal dysfunction at some point in time during treatment. Evaluation of kidney function is not
routinely done in most HIV public clinics. Identification of renal dysfunction is key in resource constrained settings
because managing patients with end stage renal disease is costly.
Method: This was a cross-sectional study conducted at an outpatient clinic in 2018 involving patients on TDF for at
least 6 months who were 18 years or older. Patients with documented kidney disease and pregnancy were
excluded. Estimated glomerular filtration rate (eGFR) was calculated using the CKD-Epi formula. Renal dysfunction
was defined as any of the following; either eGFR< 60 mL/min/1.73m2,or proteinuria of ≥2+ on urine dipstick,
glycosuria with normal blood glucose. Electrolyte abnormalities were also documented.
Results: We enrolled 278 participants. One hundred sixty nine (60.8%) were females, majority 234(84.2%) were < 50
years old, 205 (73.74%) were in WHO stage 1, most participants 271(97.5%) in addition to TDF were receiving
lamivudine/efavirenz. The median age was 37(IQR 29–45) years; median duration on ART was 36 (IQR 24–60)
months. The prevalence of renal dysfunction was 2.52% (7/278). Most noted electrolyte abnormality was
hypocalcaemia (15.44%).
Conclusions: The prevalence of renal dysfunction was low though some participants had hypocalcaemia.
Screening for kidney disease should be done in symptomatic HIV infected patients on TDF.
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Background
People living with HIV (PLHIV) are living longer and as
a result face a challenge of increasing morbidity from
non-communicable diseases-NCDS [1, 2]. Kidney disease
manifesting as renal dysfunction is one of the emerging
NCDs in the world, with a varying prevalence of 13.9 to
48.5% [3, 4] . There is increasing concern that HIV being
epidemic in this region, is contributing to the increasing
prevalence of renal dysfunction in Sub-Saharan Africa
[3] The etiology of renal dysfunction includes; HIV-
associated nephropathy (HIVAN), HIV immune com-
plex kidney disease (HIVICK), drugs used for treatment
of opportunistic infections, antiretroviral therapy (ART),
use of non-steroidal anti-inflammatory drugs (NSAIDS),
herbal medicines, other co morbid conditions namely
diabetes mellitus, hypertension and Hepatitis B & C.
The consequences of renal dysfunction range from acute
kidney injury (AKI), chronic kidney disease, end stage
renal disease (ESRD) or death [5]. In countries with
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limited resources curative services for NCDs are an obvi-
ous strain to government rendering prevention as the
best strategy [4, 6, 7]. Prevention involves identifying
those conditions early, continuous health education/
screening of the affected people and appropriate referral
for proper management to delay complications.
The 90–90-90 UNAIDS strategy by 2020 [8] is not far
away, but with it more people will be on ART coupled
with the “test and treat approach”, whereby an individual
testing positive for HIV is initiated on ART regardless of
the CD4 or WHO clinical stage [9]. People living with
HIV will be on ART for a long time yet with advancing
age renal dysfunction deteriorates [10]. When ART pro-
grams started in Uganda, there was a lot of emphasis on
initial evaluation of patients before starting treatment,
but as the number of patients has increased this has not
always been the case [11]. With regard to ART, patients
on Tenofovir disproxil fumarate (TDF)based regimen
from a number of studies are more prone to decline in
kidney function. Other factors associated with renal dys-
function include, being older, being female, African-
American ethnicity, low weight, low CD4 count, high
viral load and having co-morbid conditions [12]. The
cost of managing a patient with ESRD is high yet early
identification with simply estimating glomerular filtra-
tion rate and a urine dipstick can help. The problem is
even made worse by presentation of renal dysfunction
being asymptomatic, late patient presentation, having
few nephrologists and few/costly renal replacement ther-
apies [13]. There are few studies quantifying the magni-
tude of renal dysfunction among HIV positive patients
in sub-Saharan Africa and no renal registries/inadequate
data in the region [14, 15]. This study aimed to quantify
the magnitude of renal dysfunction among HIV infected
patients receiving TDF based ART.
Methods
Study site
The study was carried out at the Mulago Commu-
nicable Disease Clinic under the directorate of
medicine situated in Kampala, Uganda. Mulago-
Kiruddu hospital is home to the directorate of medi-
cine since May 2016; running different medical out-
patient and inpatient clinics. The communicable
disease clinic is supported by Makerere University
Joint AIDS Program (MJAP), runs on Fridays as an
outpatient clinic, and mainly attends to HIV in-
fected patients. All services are provided free of
charge to the public.
Study design
We conducted a cross sectional study with the sample
size calculated based on the Kish and Leslie formula for
prevalence studies. The sample size was calculated as
396 (based on prevalence of 18.6,Wantakisha et al) [16]
at a precision α of 0.05.We included adults aged 18 years
and above on TDF based ART for at least 6 or more
months. Participants were enrolled consecutively for
convenience of which 278 met the inclusion criteria.
Reasons for exclusion included; being on TDF for less
than 6 months, pregnancy and refusal to join the study
(Reasons given included; limited time, need to consult
spouse, no interest in participating in the study and
some were already in other studies).
Study procedures
Patients, who fulfilled the study criteria were enrolled,
interviewed for demographic and social data. Medical
history was collected and physical examination per-
formed. Blood pressure measurement was done in stand-
ard way (after patient had rested for 5 min, in sitting
position and two measurements were taken). Patients
with a value greater than 140/90 mmHg were considered
hypertensive. Blood pressure > 140mmHg was consid-
ered systolic hypertension and a value of > 90mmHg
considered diastolic hypertension. Nutritional assess-
ment was done using body mass index (BMI), obtained
using the formula body weight in kilograms divided by
height squared in meters. Venous blood was collected
for renal function test and electrolytes (serum creatinine,
urea, potassium, calcium and phosphate). Reference la-
boratory ranges for electrolytes;
 Potassium 3.5–5.0 mmol/l
 Calcium 2.2–2.7 mmol/l
 Phosphate 0.97–1.45 mmol/l
Results for the electrolytes were reported as hypo or
hyper depending on these reference ranges.
Following aseptic technique, 10 mL of venous blood
was drawn from each participant into a syringe. Seven
mills (7mls) (of the 10mls) of blood for renal function
tests & electrolytes (potassium, calcium phosphate) was
placed in a red top vacutainer and centrifuged. Four mls
of serum were then put in crial vials. The remaining 3
mls (of the 10 mL) were placed in a grey vacutainer bot-
tle (to determine blood sugar). All these were adequately
packaged in Ziploc bags and carrier for processing in old
Mulago clinical laboratory. Renal function tests, electro-
lytes and blood sugar were determined using an auto-
mated Abott Machine, Architect plus-Ci Chemistry and
immunochemistry analyzer.
Each participant was provided with a sterile urine con-
tainer and educated briefly about provision of 20 mL of
a mid-stream urine which was analyzed using a dipstick
on the same day to determine presence of leucocytes, ni-
trites, hematuria or glucose. Estimated glomerular
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filtration rate (eGFR) was calculated using the Chronic
kidney Disease Epidemiology Collaboration (CKD-EPI)
formula which is more accurate than the Cockcroft gault
formula [17]. For this study renal dysfunction was noted
as either eGFR less than 60 ml/min/1.73m2or proteinuria
of ≥2+ with glycosuria but normal blood sugar. As per
Kidney foundation’s kidney Disease outcome quality Ini-
tiative (K/DOQI),eGFR< 60 for 3 months implies chronic
kidney disease [6]. To capture patients of TDF nephro-
toxicity we assessed proteinuria,glucosuria and serum
glucose [18].
Statistical analysis
Data was analyzed using STATA 14.0 software package.
Continuous variables were summarized as means and
standard deviation for normally distributed data, me-
dians and interquartile ranges for not normally distrib-
uted data. Categorical variables were summarized as
frequencies, percentages and also in tables and figures.
Tests for the significance of association were made using
the Pearson chi-square (X2) test for categorical variables
and independent sample t test for continuous variables.
The outcome variable was renal dysfunction.
Results
From November 2017 through March 2018 (for 4
months), eight hundred eight (808) patients were con-
secutively screened in Mulago Communicable Disease
Clinic for study enrolment. Three hundred five (305) pa-
tients met the eligibility criteria and were enrolled. Of
these, 278 were entered into the final analysis and 27 pa-
tients were excluded due to incomplete data. One hun-
dred sixty nine (60.8%) were female, majority 234
(84.2%) were < 50 years old. Median age was 37 (IQR
29–45) years. One hundred nineteen (42.81%) were mar-
ried, 141(50.72%) had a primary education, 250(89.93%)
had formal employment, 252(83.45%) resided in
Kampala and 81 (29.14%) consumed alcohol. (Table 1).
Clinical and laboratory characteristics (Table 2)
The median duration on ART was 36 IQR (24–60)
months, 271 (97.48%) were on TDF/3TC/EFV,
152(72.38%) had CD4 ≥ 200 cells/ml, 109 (86.51%) had
viral load of < 1000 copies/ml, 205(73.74%) were in
WHO clinical one,155(55.76%) had a normal BMI,
38(13.67%) had systolic hypertension, 42(15.11%) had
diastolic hypertension and 270(97.12%) had no concur-
rent opportunistic infections. Three (1.08%) had random
blood sugar ≥11.1 mmol/l, 10 (3.6%) had proteinuria of
≥2+, 4(1.44%) tested positive for nitrites, 7(2.52%) had
hematuria and 2(0.72%) had glycosuria.
Electrolyte abnormalities among study participants
(Table 3)
Ten (3.59%) had hypophosphatemia, 11(4.44%) had
hyperphosphatemia, 15(5.26%) had hyperkalemia,
3(1.32%) had hypokalemia, 43 (15.44%) had hypocalcae-
mia and 2 (0.67%) had hypercalcemia.
Prevalence of renal dysfunction among study participants
Of the 278 subjects, 7 were found to have eGFR < 60ml/
min/1.73m2, ten [10] patients had proteinuria (but no
glycosuria), 2 patients had glycosuria (but no protein-
uria). Therefore prevalence of renal dysfunction was
2.52% (7/278). (See Table 4).
Discussion
We aimed to determine the prevalence of renal dysfunc-
tion among HIV infected patients receiving TDF attend-
ing Mulago Communicable Disease Clinic in Uganda.
Defining renal dysfunction as eGFR < 60mL/min/1.73
m2 or proteinuria of ≥2+, with glycosuria on dip stick
Table 1 Socio-demographic Characteristics of the study
participants receiving TDF based ART ≥6 months at Mulago
Communicable disease clinic




Age (Years) median,(IQR) 37 (29–45)
18–34 128 46.04
35–49 106 38.13














Outside Kampala 46 16.55
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urinalysis with a normal blood sugar. We found a low
prevalence of 2.52%. This is in agreement with other
studies that show that use of TDF is associated with
modest renal dysfunction.
Udeme et al 2018 in a systematic review and meta-
analysis found an overall prevalence of CKD as 6.4%.
Chronic kidney disease was defined as eGFR < 60ml/
min using any of the three formulas (i.e. Cockcroft,
MDRD and CKD-EPI). In this study contributing factors
included WHO region, hypertension and Diabetes Melli-
tus. Reid et al 2008 in a study (DART trial) done in
Uganda and Zimbabwe, noted a prevalence of 7% among
patients on ART, followed up for 96 weeks. Majority
(74%) of the patients were receiving TDF based therapy.
In this study Glomerular filtration rate was assessed using
the Cockcroft gault formula which has its limitations.
The variability of different prevalence rates in the stud-
ies is attributable to; the different definitions of renal dys-
function, different methods used to estimate GFR and
patient characteristics (age, ART regimen, advanced HIV
and presence/absence of other co-morbidities) [5, 10, 19].
The low prevalence in our study could be explained by
the small sample size, being an outpatient clinic receiving
not very critically sick patients, the possible effect of ART
improving kidney function [20] and use of the CKD-Epi for-
mula which is a more accurate method of assessing eGFR in
asymptomatic patients compared to other formulas [17].
We assessed three serum electrolytes in this study
namely; Potassium, Calcium and Phosphate. Albumin
and vitamin D levels were not assessed. We noted
mainly Hypocalcaemia (15.44%), Hyperkalemia (15%)
and hypophosphatemia (3.59%).Hypocalcaemia has been
found at a higher prevalence in other studies among
HIV infected patients compared to the general popula-
tion. Vitamin D deficiency is very common among HIV
patients and may be the most reasonable explanation
[21, 22]. TDF may cause vitamin D deficiency through
impairment of tubular dysfunction leading to decreased
1-alpha hydroxylation of vitamin D and lower tubular
reabsorption of vitamin D binding protein. There are
also studies that have found an association with efavir-
enz use and low vitamin D levels which could also po-
tentially explain the hypocalcaemia since 97% of their
patients were on efavirenz.
Table 2 Clinical characteristics of the study participants
receiving TDF based ART ≥6 months at Mulago Communicable
Disease Clinic
Characteristics Frequency(n) Percentage (%)
BMI
18.5–24.9-Normal 155 55.76
25–29.9- Overweight 78 28.06







Most recent (CD4+ cell count cells/ml)
< 200 58 27.62
≥ 200 152 72.38
Viral load (copies/ml)
< 1000 109 86.51





< 11.1 mmol/l 275 98.92
> 11.1 mmol/l 3 1.08
Protein present in urine
≥ 2+ (present) 10 3.6










Table 3 Electrolyte abnormalities among study participants
receiving TDF based ART ≥6 months at Mulago Communicable
Disease Clinic
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For patients with hypophosphatemia, data is similar to
studies elsewhere that demonstrate that TDF is associ-
ated with Proximal tubulopathy manifesting as Fanconi
syndrome [20, 23]. Rarely all the components of FS
occur in one patient. Because of the wasting of Phos-
phate, potassium and amino acids in urine they tend to
be low in serum. Hypophosphatemia could have a dual
origin: decreased proximal reabsorption of phosphate
and decreased vitamin D activation. Another possible
cause of low phosphate in serum is the possibility of
Vitamin D deficiency that is prevalent in HIV infected
patients [22, 23]. Hyperkalemia may be explained by the
possibility of these patients having had acute kidney in-
jury, chronic kidney disease and medications e.g.Cotri-
moxazole [5, 24]. In this study majority of the patients
were asymptomatic, though not enough information as
regards symptoms was collected.
Proteinuria is an important marker of renal dys-
function, however for this study we tried to identify
an operational definition that could in cooperate TDF
nephrotoxicity. Other studies that have looked at pro-
teinuria have given higher values of renal dysfunction.
And this also helps capture the decline in renal dys-
function early to mitigate progress to ESRD.
Our study had some limitations; the small sample size (as
a result we were unable to assess factors associated with
renal dysfunction), missing information for some patients
(e.g. CD4 and Viral load) which were not done/documented
by primary health care giver and no baseline renal function
to assess change over time (routine testing of renal function
tests was no longer being done by the primary health care
giver (findings from the DART trial) and we had limited
time for the study to check the baseline levels). The results
we got will form as baseline for future reference.
Conclusions
The prevalence of renal dysfunction among HIV infected
patients receiving TDF was low at 2.52% and hypocalcae-
mia was the most common electrolyte abnormality noted.
Renal dysfunction occurs at a low rate in our settings
however when assessed should include serum electrolytes.
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